Martin R. Gill

University of Oxford

H指数:28

被引数:3,468

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ruthenium(ii) polypyridyl complexes and the DNA damage response: mechanisms and therapeutic implications

钌(II)多吡啶配合物与DNA损伤应答：机制和治疗意义

RSC Medicinal Chemistry

IF3.6

2026-05-010

Nitro-substituted ruthenium(II) polypyridyl complexes synergise with ATR inhibitors to enhance replication stress in cancer cells

硝基取代的钌(II)多吡啶配合物与ATR抑制剂协同作用以增强癌细胞中的复制应激

dalton trans.

IF0

2026-04-170

PRE

Olaparib synergy screen reveals Exemestane induces replication stress in triple-negative breast cancer

奥拉帕尼协同筛选揭示依西美坦在 triple-negative breast cancer 中诱导复制应激

Molecular Oncology

IF4.5

2025-07-130

OAAI

Targeting DNA mismatches with metal complexes

靶向DNA错配的金属配合物

Journal of Inorganic Biochemistry

IF3.2

2025-06-240

PRE

Cyrene™ as a green alternative to N,N′-dimethylformamide (DMF) in the synthesis of MLCT-emissive ruthenium(ii) polypyridyl complexes for biological applications

DALTON TRANSACTIONS

IF3.3

2024-01-011

A bipyridyl quinoline ruthenium(II) complex as a Light Switch for living cell mitochondrial singlet oxygen

SENSORS AND ACTUATORS B-CHEMICAL

IF7.7

2023-08-011

PRE

Discovery of Ruthenium(II) Metallocompound and Olaparib Synergy for Cancer Combination Therapy

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2023-05-155

OAAI

Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells

SCIENTIFIC REPORTS

IF3.9

2023-01-268

OAAI

Ruthenium(II) Polypyridyl Complexes as FRET Donors: Structure- and Sequence-Selective DNA-Binding and Anticancer Properties

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

IF15.6

2023-01-0627

OAAI

Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features

NUCLEIC ACID THERAPEUTICS

IF4.7

2022-06-0132

OAAI

A Ruthenium(II) Polypyridyl Complex Disrupts Actin Cytoskeleton Assembly and Blocks Cytokinesis

钌 (II) 多吡啶复合物破坏肌动蛋白细胞骨架组装并阻止胞质分裂

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

IF16.9

2022-05-0313

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

介孔二氧化硅纳米粒子作为肿瘤治疗药物载体的研究进展

PHARMACEUTICS

IF5.5

2021-01-2479

OAAI

Synthesis and Optimization of Mesoporous Silica Nanoparticles for Ruthenium Polypyridyl Drug Delivery

用于钌多吡啶药物输送的介孔二氧化硅纳米颗粒的合成与优化

PHARMACEUTICS

IF5.5

2021-01-2422

OAAI

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy

CHEMMEDCHEM

IF3.4

2020-09-1036

OAAI

Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition

ACS CHEMICAL BIOLOGY

IF3.8

2020-01-0313

OAAI

An 111In-labelled bis-ruthenium(ii) dipyridophenazine theranostic complex: mismatch DNA binding and selective radiotoxicity towards MMR-deficient cancer cells

CHEMICAL SCIENCE

IF7.4

2020-01-0113

OAAI

Radiolabeled Oligonucleotides Targeting the RNA Subunit of Telomerase Inhibit Telomerase and Induce DNA Damage in Telomerase-Positive Cancer Cells

CANCER RESEARCH

IF16.6

2019-09-1318

OAAI

Combining ruthenium metallo-intercalators and targeted radionuclide therapy for EGFR-overexpressing oesophageal cancer

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Using Nanoscopy To Probe the Biological Activity of Antimicrobial Leads That Display Potent Activity against Pathogenic, Multidrug Resistant, Gram-Negative Bacteria

ACS NANO

IF16

2019-04-0950

OAAI

NF-κB hijacking theranostic Pt(II) complex in cancer therapy

THERANOSTICS

IF13.3

2019-01-0115

OAAI

Martin R. Gill

个人简介

教育背景

工作经历

荣誉奖项

研究方向